From the Austin American-Statesman:
http://www.statesman.com/business/conte ... 4dobi.html
Here's a brief run-down...
Hot tip and high hopes; then the stock sank
Byron told Brian, who told Steve and Bobby and Ruben. Ruben may or may not have told Barbara.
Kids passing around schoolyard gossip?
Not quite. It's the way a stock tip buzzed through a network of friends in Austin last year, prompting some to invest hundreds of thousands of dollars in a New Jersey company that claims to have the next big thing in breast-cancer diagnosis.
So far, the bets they made on DOBI Medical International Inc. haven't panned out.
Most of the Austin investors — who include
Brian Vodicka, a retired lawyer and real-estate investor, and Bobby Inman, the acting dean of the LBJ School of Public Affairs — bought shares last year at the equivalent of $2 each in a special offering for wealthy investors. On Friday, the shares closed at 21 cents.
The collapse of DOBI's share price has prompted one lawsuit in U.S. District Court in Austin. The suit, brought by Vodicka and 27 other plaintiffs, alleged that the company, its former investment bank and a large shareholder engineered a scheme to drive up the share price so some stockholders could dump their shares.
That case was dismissed last month on procedural grounds, but another lawsuit is likely to be filed this week, according to the plaintiffs' new lawyer, Mark Kincaid.
DOBI officials contend that the plaintiffs are suing simply because they're upset over the low stock price and that they have no evidence the company did anything improper.
The story of DOBI shows that even sophisticated investors can sometimes put large sums of money into untested companies largely on the word of a friend of a friend.
It started at lunch in early 2004. Byron Hill passed on a tip to his friend Brian Vodicka.
The company's appeal was "the advances they were making in the industry, the technology design that could revolutionize breast imaging," Hill said.
"It had the potential to be a 10-bagger," Vodicka said, using stock-market lingo for a company whose share price rises tenfold.
That kind of return would help Vodicka recoup some losses from the recent bear market and allow him to donate to favorite causes such as symphony orchestras.
Vodicka says he didn't need the money. At 46, he has been retired from the practice of law for 10 years, having done extremely well investing in apartment complexes as Austin started to recover from the 1980s real estate bust.
DOBI Medical was a risky business because it hinged on one product, the ComfortScan. The company says the machine uses high-intensity light and gentle pressure on the breast to identify "vascular abnormalities" associated with malignancies. It "has the potential to improve the physician's ability to correctly diagnose breast cancer," the company says, and the scan takes just 45 seconds.
The ComfortScan was a long way from approval by the U.S. Food and Drug Administration, not to mention acceptance by hospitals, physicians and insurers.
The potential was huge, though: 35 million mammograms a year are done in the United States. At about $140,000 each, the ComfortScan would cost up to 75 percent less than standard mammography machines, according to the company.
But there were less dazzling facts about DOBI:
•It trades on the over-the-counter exchange, a lightly regulated market for thousands of small companies that don't meet the financial standards of the major stock exchanges.
•The company has burned through $31 million, most of it raised from investors, in its six-year life while generating insignificant sales and consistently missing its own financial and product-launch forecasts.
The company says its auditors issued numerous "going concern" warnings, signaling their doubt that the company can survive without continued additional investment.
•An investment bank raising money for the company has been sanctioned by securities regulators, and its president was once suspended for 20 days and fined $35,000 for not disclosing that his firm, Sterling Financial Investment Group, had loaned money to DOBI and would be paid in company shares, according to the National Association of Securities Dealers.
•DOBI Medical's outside scientific expert, Dr. William Li of Cambridge, Mass., is a paid director for the company and owns 63,000 shares of its stock. Li also claims, in company documents, to be a Harvard Medical School professor, but Kate Butler, a spokeswoman for the school, said there is no record of him.
Vodicka said he trusted Hill's word on the company "because of his medical marketing expertise."
Vodicka decided to invest $400,000. And if DOBI Medical "was about to take off like a rocket," Vodicka said, "I wanted my friends to take off, too."
He spread the word to his wide circle of friends.
Vodicka's twin brother
Gary, a Dallas lawyer, invested. So did their mother. Vodicka's housemate, Steve Aubrey, an outdoor lighting designer, says that he put in $150,000 and that his parents invested as well.
Inman, a former deputy director of the CIA, invested $150,000 after learning of the company from Vodicka. Barbara Hearst kicked in $250,000.
Psychologist Crowley, a friend of Vodicka's for 20 years, invested the most, $500,000, which he said is "a big piece" of his savings. "I was convinced beyond a doubt ,or I never would have done it," he says.
All told, Vodicka and his friends contributed a good chunk of the $5.1 million that DOBI Medical raised in its private placement in the summer of 2004.

When twin brothers
Gary, left, and Brian
Vodicka got their day in court last month, the federal lawsuit brought by them and 25 other DOBI Medical investors was dismissed on procedural grounds. Another lawsuit is likely to be filed this week, the plaintiffs' new lawyer said.